Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4HBAP, also known as para-topolin, is an aromatic cytokinin small molecule developed by Pyratine LLC for dermatological applications. As a plant growth regulator, it has been adapted for human skin care due to its ability to delay cellular senescence and provide antioxidant effects. It is typically used in topical formulations at a 0.10% concentration to treat signs of facial photodamage, including fine lines, coarse wrinkles, skin roughness, and hyperpigmentation. Clinical studies have also demonstrated its efficacy in reducing facial erythema and non-inflammatory acne lesions. 4HBAP is noted for its ability to enhance skin hydration and barrier function without the irritation or side effects often associated with traditional anti-aging treatments like retinoids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4HBAP.